Idiopathic late-onset dementia (ILOD) describes impairments of memory, reasoning and/or social abilities in the elderly that compromise their daily functioning. Dementia occurs in several major prototypical neurodegenerative disorders that are currently defined by neuropathological criteria, most notably Alzheimer’s disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD) and hippocampal sclerosis of aging (HSA). However, people who die with ILOD commonly exhibit mixed pathologies that vary within and between brain regions. Indeed, many patients diagnosed with probable AD exhibit only modest amounts of disease-defining amyloid β-peptide plaques and p-Tau tangles, and may have features of FTD (TDP-43 inclusions), Parkinson’s disease (α-synuclein accumulation), HSA and vascular lesions. Here I argue that this ‘mosaic neuropathological landscape’ is the result of commonalities in aging-related processes that render neurons vulnerable to the entire spectrum of ILODs. In this view, all ILODs involve deficits in neuronal energy metabolism, neurotranspheric signaling and adaptive cellular stress responses, and associated dysregulation of neuronal calcium handling and autophagy. Although this mosaic of neuropathologies and underlying mechanisms poses major hurdles for development of disease-specific therapeutic interventions, it also suggests that certain interventions would be beneficial for all ILODs. Indeed, emerging evidence suggests that the brain can be protected against ILOD by lifelong intermittent physiological challenges including exercise, energy restriction and intellectual endeavors; these interventions enhance cellular stress resistance and facilitate neuroplasticity. There is also therapeutic potential for interventions that bolster neuronal bioenergetics and/or activate one or more adaptive cellular stress response pathways in brain cells. A wider appreciation that all ILODs share age-related cellular and molecular alterations upstream of aggregated protein lesions, and that these upstream events can be mitigated, may lead to implementation of novel intervention strategies aimed at reversing the rising tide of ILODs.

**HISTOPATHOLOGICAL LANDSCAPES OF PROTOPYTICAL DEMENTIAS**

The brain regions that suffer the greatest amount of synapse loss and neuronal death in ILOD include the hippocampus, entorhinal cortex, medial temporal lobe, frontal cortex and inferior parietal cortex. However, the amount of neurodegeneration varies considerably between brain regions and among individuals, which may explain, in part, the inter-individual variability in the type and magnitude of deficits in different cognitive domains. Neurons that degenerate often exhibit accumulations of aggregated proteins that form fibrillar or more amorphous inclusions within their cell bodies and neurites, and/or form extracellular deposits of aggregated proteins. Together with an understanding of the genetic causes of rare cases of Alzheimer’s disease (AD), Parkinson’s disease (PD) and FTD, the specific proteins that accumulate within or outside of cells in the affected brain regions have been used to classify some ILODs as specific diseases. For example, a diagnosis of AD is ultimately established by semiquantitative analysis of neurofibrillary tangles (comprised of hyperphosphorylated Tau protein; p-Tau) and the density of large extracellular aggregates of amyloid β-peptide (Aβ) that form amyloid plaques. Mutations in the β-amyloid precursor protein (APP) and presenilin 1 that cause early-onset familial AD result in increased production of aggregation-prone neurotoxic forms of Aβ, neurofibrillary tangle formation and associated neuronal death. However, whereas in late-onset AD the amyloid and p-Tau pathologies occur predominantly in cerebral cortical regions, in familial AD subcortical structures such as the striatum are also often severely affected. In this section, I describe key histopathological criteria used to assign a specific/prototypical disease diagnosis to ILOD patients, and also briefly summarize genetic aberrancies that are known to cause familial early-onset dementias. As there exists an immense literature on these disorders, I reference mainly research articles in which key original research articles are cited.

**Alzheimer’s disease**

A diagnosis of AD requires that the patient has a clinical history of progressive memory impairment and exhibits two defining histopathological features of AD, the presence of abundant extracellular Aβ plaques that often exhibit dystrophic neurites (neuritic plaques), and intraneuronal fibrillar aggregates of p-Tau (neurofibrillary tangles) (Figure 1a,b). The severity of the Aβ plaque pathology is ranked from minimal (Thal stage 1) to severe (Thal stage 5), and the neurofibrillary tangle pathology is ranked on a 6-point scale from minimal (Braak stage I) to severe (Braak stage VI). However, many cognitively normal elderly subjects
Frontotemporal dementia

Some inherited cases of FTD are caused by mutations in the gene encoding Tau. While progressive dementia occurs in FTD, many patients first present with psychiatric symptoms such as apathy, impulsive behavior and aggressiveness. Motor dysfunction similar to PD also occurs in many FTD patients. Cognitive symptoms include attention deficits and executive dysfunction. There is considerable inter-individual variability in the clinical presentation of FTD patients, even within the same family. The histopathological features of FTD are dominated by intraneuronal accumulation of p-Tau amorphous aggregates and filaments. There is little or no Aβ pathology in FTD (Figure 1c). The p-Tau pathology is usually confined to the cerebral cortex gray matter and white matter. Atrophy of the frontal and temporal lobes is severe. Mutations in the gene encoding transactive response DNA-binding protein 43 (TDP-43) cause some cases of FTD, and cytoplasmic inclusions containing phosphorylated and ubiquitinated forms of TDP-43 are prominent in FTD. Recently, it was found that hexanucleotide repeat expansions in C9ORF72 (a non-coding region on chromosome 9) are responsible for many cases of inherited and sporadic FTD and amyotrophic lateral sclerosis. TDP-43 pathology is a prominent feature in patients with C9ORF72 hexanucleotide repeat expansions. In addition, recent findings suggest that the C9ORF72 hexanucleotide repeat DNA is transcribed and the mRNA is translated into dipeptide repeat proteins that aggregate and can be neurotoxic.

Hippocampal sclerosis of aging

Progressive atrophy of the hippocampus is a common feature of AD that is associated with cognitive decline. However, many subjects with extensive hippocampal atrophy, and who are clinically indistinguishable from AD patients, exhibit only minimal Aβ plaque and p-Tau pathologies. Instead these patients suffer massive neuronal loss and gliosis in the CA1 region of the hippocampus and the adjacent subiculum, the defining pathology of HSA. HSA is most common in patients over the age of 80, affecting >20% of those diagnosed with probable AD. While Aβ plaque and p-Tau pathologies are not prominent in HSA, TDP-43 pathology is common, with TDP-43 cytoplasmic inclusions occurring in neurons and astrocytes of the hippocampus and associated neocortical regions in the frontal and temporal lobes, and the amygdala. The genetics of HSA are largely unexplored. Families with Mendelian inheritance of HSA have not been reported. However, recent studies have associated single-nucleotide polymorphisms in genes that encode the mitochondrial potassium channel protein ABCC9, the growth factor-like glycoprotein progranulin and the lysosome/autophagy-associated protein TMEM106B with increased risk of HSA. These findings suggest that alterations in the regulation of neuronal excitability, neurotrophic support and lysosome function contribute to the pathogenesis of HSA, consistent with the notion that all ILODs involve impaired neuronal energy metabolism, neurotrophic signaling, calcium handling and autophagy.

LBD and PD dementia

The symptoms of patients with LBD include cognitive impairment, hallucinations, depression, intermittent confusion and PD-like motor signs (bradykinesia, rigidity and myoclonus). Aggregates of α-synuclein in the cytoplasm of neurons throughout the cerebral cortex and subcortical structures is the characteristic histopathological feature of LBD17 (Figure 1d). In some neurons the α-synuclein aggregates completely fill the cytoplasm of the cell body (so-called ‘Lewy bodies’), whereas in other neurons smaller granular aggregates are evident. Notably, α-synuclein aggregates are also evident in axon terminals where they may
Mosaic nature of dementia: implications for intervention

MP Mattson

MOSAIC NEUROPATHOLOGICAL LANDSCAPES ARE COMMON IN ILOD

The heterogeneity of the neuropathological landscape of ILOD is now widely appreciated and described in the literature.2,22–25 The presence of specific aggregated and posttranslationally modified (hyperphosphorylated and poly-ubiquitinated) proteins has been used to classify the cellular pathology of ILOD with the intention of labeling individual patients with a disease diagnosis. Early molecular genetic studies of AD, PD and FTD provided justification for the latter approach because APP mutations can cause dementia.26 α-synuclein mutations can cause PD and Tau mutations can cause FTD; the affected individuals exhibit predominantly Aβ, α-synuclein and Tau pathologies, respectively. However, many or perhaps most cases of ILOD are not readily placed within an AD, PD or FTD ‘disease bin’. Instead, there is a mosaic of histopathological phenotypes among ILOD patients (Figure 1). For example, in some cases, TDP-43 inclusions and HSA may be robust, with Aβ and p-Tau pathologies minimal. Other ILOD patients with a similar cognitive deficit profile may have abundant neuritic plaques and neurofibrillary tangles in the entorhinal cortex, hippocampus and inferior parietal cortex, and so are given a diagnosis of AD. Patients with LBD often exhibit hippocampal sclerosis and TDP-43 inclusions in hippocampal neurons.27 In one study of 342 subjects diagnosed with AD based on Aβ and p-Tau pathology, 193 of the subjects exhibited TDP-43 pathology.28 In the latter study, TDP-43 pathology was strongly correlated with the type and magnitude of the histopathological abnormalities and cognitive function. At one extreme are individuals with abundant Aβ pathology who are cognitively normal, and at the other extreme are those with extensive neuronal degeneration but relatively modest accumulation of proteopathic proteins.29,30 And so for each type of proteopathic alteration (Aβ plaques, p-Tau, α-synuclein aggregates, TDP-43 inclusions) any particular ILOD patient can be positioned somewhere within the distribution range of all ILOD patients (Figure 1). Assuming each of the different aggregation-prone proteins contributes to the dysfunction and degeneration of neurons in ILODs, then it follows that there are additional factors that determine whether or not neurons succumb to the cytotoxic action of the proteopathic protein(s). It should also be noted that a proteopathic protein may not be a critical factor in the mechanism of neuronal degeneration in some cases of ILOD; for example, the pathological landscape of HSA can be largely devoid of pathogenic protein aggregates. The remainder of this article considers the age-related cellular and molecular mechanisms that may render neurons vulnerable to ILOD, and how those mechanisms can be modified by environmental factors, with a focus on diet, exercise and intellectual challenges throughout the lifespan.

NEURONAL VULNERABILITY IN ILOD CAN OCCUR UPSTREAM AND DOWNSTREAM OF PROTEOPATHIC PROTEINS

Histopathological studies of the brains of cognitively normal octogenarians, nonagenarians and centenarians have shown that essentially all very old subjects exhibit one or more neuropathological features of both AD and PD, often with distributions not typical of late-onset AD and ILODs. For example, affected members of a family with the presenilin 1 S170F mutation developed dementia in their third decade of life and, in addition to classic AD pathology, they exhibited Lewy bodies in the brainstem, limbic structures and neocortex.28 The mixed neuropathologies among subjects with different mutations in the same gene strongly suggest that other genetic factors and environmental factors impact the disease process.

In ILOD, advancing age is the major risk factor and provides a progressively unfavorable environment within the brain, and evidence from studies of animal models and human subjects suggests that the development of such a pro-neurodegenerative cellular environment can be accelerated or retarded by genetic and environmental factors.29,30 While the majority of dementia patients exhibit pathology commensurate with the severity of their cognitive impairment, there is often discordance between the type and magnitude of the histopathological abnormalities and cognitive function. At one extreme are individuals with abundant Aβ pathology who are cognitively normal, and at the other extreme are those with extensive neuronal degeneration but relatively modest accumulation of proteopathic proteins.22–25 And so for each type of proteopathic alteration (Aβ plaques, p-Tau, α-synuclein aggregates, TDP-43 inclusions) any particular ILOD patient can be positioned somewhere within the distribution range of all ILOD patients (Figure 1). Assuming each of the different aggregation-prone proteins contributes to the dysfunction and degeneration of neurons in ILODs, then it follows that there are additional factors that determine whether or not neurons succumb to the cytotoxic action of the proteopathic protein(s). It should also be noted that a proteopathic protein may not be a critical factor in the mechanism of neuronal degeneration in some cases of ILOD; for example, the pathological landscape of HSA can be largely devoid of pathogenic protein aggregates. The remainder of this article considers the age-related cellular and molecular mechanisms that may render neurons vulnerable to ILOD, and how those mechanisms can be modified by environmental factors, with a focus on diet, exercise and intellectual challenges throughout the lifespan.

© 2015 Japanese Society of Anti-Aging Medicine/Macmillan Publishers Limited npj Aging and Mechanisms of Disease (2015) 15003
the opening of voltage-gated Na⁺ and Ca²⁺ channels, and Ca²⁺ influx, which triggers glutamate release from the presynaptic terminal. Glutamate activates postsynaptic ionotropic AMPA and N-methyl-D-aspartate (NMDA) receptors, resulting in Ca²⁺ influx and activation of kinases and transcription factors that regulate various acute and long-term adaptive responses of the neuron. Excessive sustained activation of glutamate receptors can cause degeneration of the synapse and neuronal death by activating proteases, impairing mitochondrial function and promoting oxidative stress.

Early studies provided evidence that during the process of aggregation on the membrane of neurons and synapses Aβ causes lipid peroxidation, which impairs the function of ion-motive ATPases, and glucose and glutamate transporters, destabilizes Ca²⁺ homeostasis, and renders the neurons vulnerable to excitotoxicity. Importantly, several adverse conditions that occur in the brain during normal aging and that are exacerbated in ILOD may increase the vulnerability of neurons to the toxic actions of Aβ, p-Tau, α-synuclein and TDP-43 (Figure 2). These conditions include impaired bioenergetics/mitochondrial function, oxidative stress, inflammation, and impaired proteasome- and autophagy-mediated removal of damaged proteins and organelles. In addition, reductions in neurotrophic factor support as the result of decreased expression of the trophic factors and/or impaired signaling downstream of the neurotrophic factor receptors occurs during brain aging and more so in ILOD. For example, reduced expression of brain-derived neurotrophic factor (BDNF) and impaired insulin/insulin-like growth factor signaling occurs in the hippocampus in aging and AD. Both BDNF and insulin-like growth factor 1 can protect neurons in experimental models of AD.

Data suggest that aging and stress-related cellular energy deficits, excessive activation of glutamate receptors and oxidative stress contribute to the accumulation of p-Tau and neurofibrillary degeneration. FTD-causing Tau mutations may promote neuronal degeneration by perturbing cellular Ca²⁺ regulation and impairing autophagy. Recent studies suggest that pathogenic forms of TDP-43 render neurons vulnerable to excitotoxicity and mitochondrial dysfunction and that stimulation of autophagy can protect neurons against TDP-43 toxicity. Finally, α-synuclein pathology may result from and exacerbate neuronal oxidative stress, mitochondrial dysfunction and impaired proteasome function and autophagy. It is likely that the latter alterations first compromise synapse function, which, in turn, leads to neuronal degeneration. Indeed, it was shown that α-synuclein pathology can be lessened, and synaptic dysfunction and memory impairment can be reversed, by inhibiting α-synuclein expression in an inducible α-synuclein transgenic mouse model.

Altogether, the available data from studies of human subjects and experimental models suggest that oxidative stress, bioenergetic deficits, cellular Ca²⁺ dysregulation, impaired autophagy and inflammatory and neurotrophic cell death-promoting effects of each of the different proteopathic proteins. This knowledge suggests that interventions that bolster neuronal bioenergetics, autophagy and defenses against oxidative and excitotoxic stress may forestall development of most, if not all, cases of ILOD.

**COMPRIMED ADAPTIVE CELLULAR STRESS RESPONSES AND ILOD**

The ability of neurons in the brain to cope with stress (bioenergetic, oxidative, ionic, proteotoxic) is diminished during aging. Although thousands of studies have documented age-related decrements in molecular mechanisms that promote neuronal plasticity and survival, most can be placed within one of a relatively few general categories of stress response pathways that include neurotrophic factor signaling; defense against oxidative stress; mitochondrial function; calcium homeostasis; protein quality control; molecular waste disposal; and DNA repair.

**Neurotrophic factors**

Studies of postmortem human brain tissue samples, and of animal and cell culture models, suggest that a decline in neurotrophic support contributes to the dysfunction and degeneration of neurons in ILODs. Among the neurotrophic factors that may be compromised in ILODs, cellular Ca²⁺ dysregulation, impaired autophagy and inflammation, and mitochondrial dysfunction can be reversed in rodent and non-human primate models of AD. Although thousands of studies have documented age-related decrements in molecular mechanisms that promote neuronal plasticity and survival, most can be placed within one of a relatively few general categories of stress response pathways that include neurotrophic factor signaling; defense against oxidative stress; mitochondrial function; calcium homeostasis; protein quality control; molecular waste disposal; and DNA repair.

**Antioxidant defenses**

SOD2 protects neurons against decrements in energy availability and Aβ toxicity, and experimental reduction of SOD2 levels accelerates the onset of cognitive deficits in APP mutant transgenic AD mice. Moreover, that SOD2 deficiency can trigger Tau hyperphosphorylation suggests a role for elevated mitochondrial oxidative stress in AD, FTD and other 'Tauopathies'.

**Figure 2.** Generic age-related cellular stress and specific proteopathic abnormalities exert reciprocal cross-amplifying detrimental effects on synaptic plasticity and neuronal viability. During aging, neurons experience reduced energy availability (e.g., mitochondrial dysfunction and reduced glucose transport), increased levels of oxidative stress, perturbed cellular calcium homeostasis, impaired autophagy, and inflammation. The latter adverse changes are exacerbated by a reduced ability of neurons to respond adaptively to stress. The aggregation and associated neurotoxic activities of proteopathic proteins (Aβ, Tau, TDP-43 and α-synuclein) are promoted by metabolic, oxidative and calcium-related stress and impaired autophagy/protein degradation. Thus, cross-amplifying neurodegenerative processes result in synapse dysfunction, degeneration and neuronal death, resulting in dementia.
Healthy neurons respond to the oxidative stress triggered by excitatory synaptic activity by activating the transcription factors NF-kB and Nrf2, which, in turn induces the expression of SOD2 and heme oxygenase 1, respectively. Another defense against oxidative stress that is adversely impacted in aging and AD is the plasma membrane redox system, which includes the enzymes reduced form of nicotinamide adenine dinucleotide (NADH)-quinone oxidoreductase 1 (NQO1), NADH-ferrocyanide reductase, NADH-coenzyme Q10 reductase and NADH-cytochrome c reductase.

Cellular bioenergetics
Mitochondrial function generally declines during normal brain aging and to a greater extent in ILOD. Data suggest that electron transport chain proteins and proteins involved in the citric acid cycle are compromised in ILOD as a result of oxidative damage to the proteins and by damage to the mitochondrial DNA that encodes some of the electron transport chain proteins. Studies of patient brain tissue samples and of experimental models suggest that the alpha-ketoglutarate dehydrogenase complex of the citric acid cycle is adversely affected early in AD. In PD, complex I of the electron transport chain appears particularly prone to dysfunction. Emerging findings, elaborated upon below, suggest that interventions that enhance mitochondrial bioenergetics can counteract the neurodegenerative process in multiple ILODs including AD, PD dementia and FTD. For example, bolstering cellular bioenergetics by administration of nicotinamide or a ketone ester ameliorates learning and memory deficits in mouse models of AD. Moreover, a drug that opens mitochondrial potassium channels (diazoxide) can ameliorate cognitive defenses and lessen Aβ and p-Tau pathologies in a mouse model of AD. The latter finding is particularly interesting in light of recent evidence that polymorphisms in the gene encoding a subunit of the K⁺ channels activated by diazoxide may affect the risk of HSA.

Neuronal calcium handling
The ability of neurons to efficiently control the disposition of Ca²⁺ among subcellular compartments is compromised during aging and may result in Ca²⁺ overload and excitotoxic degeneration of synapses. It is well known that neurons are susceptible to excitotoxic damage when their bioenergetics is compromised and when they are subjected to increased levels of oxidative stress or reduced levels of neurotrophic support. One of the approved treatments for AD, memantine, acts by reducing Ca²⁺ influx through the NMDA subtype of glutamate receptor. Importantly, mutations in genes that cause early-onset AD (presenilin 1 and APP) and PD (α-synuclein and Parkin), and that may increase the risk of AD (ApoE 4) and HSA (ABCC9), impair the ability of neurons to properly regulate Ca²⁺ and may thereby render the neurons vulnerable to Ca²⁺ overload-mediated cell death. A better understanding of the pivotal molecular alterations that render neurons vulnerable to Ca²⁺ overload may suggest novel approaches for therapeutic interventions aimed at restoring cellular Ca²⁺ homeostasis.

Molecular garbage disposal
A robust alteration that occurs in neurons during aging that likely contributes to the accumulation of proteopathic proteins in ILOD is impaired autophagy and proteasome function. Intracellular accumulation of Aβ, α-synuclein and Tau may normally be prevented by targeting these proteins to the proteasome and/or lysosomes. Impaired ubiquitin-mediated proteasomal degradation of α-synuclein may result from age-related oxidative damage to proteasome proteins or excessive production of α-synuclein. Impaired lysosome function is believed to contribute to the accumulation of dysfunctional mitochondria, which are normally degraded by ‘mitophagy’. Interventions that enhance proteasome function and autophagy have been reported to counteract neuronal dysfunction and degeneration in experimental models of ILODs. For example, methylene blue enhances proteasomal degradation and improves cognitive function in a mouse model of AD, and methylene blue also enhances autophagy and thereby suppresses Tau pathology in models relevant to FTD. Dietary energy restriction (DER), which is known to stimulate autophagy, is neuroprotective in animal models of AD and PD (see ref. 30 for review). Thus, enhancement of protein quality control and removal of damaged proteins can counteract adverse conditions relevant to ILODs.

DNA damage
DNA damage in brain cells is caused predominately by free radicals and is increased during normal aging, and to a greater extent in AD and presumably other ILODs. This accumulation of DNA damage results, in part, from impaired DNA repair, particularly base-excision repair. During aging there occurs an accumulation of damage to DNA in the nuclear genome and in mitochondria. A study of human subjects provided evidence that the regulatory elements of certain genes that encode proteins involved in synaptic plasticity and adaptive stress responses exhibit a predilection for DNA damage, resulting in a corresponding reduction in levels of expression of those genes. Studies of genetically modified mice have shown that deficiencies in several DNA repair enzymes increase the vulnerability of neurons to metabolic stress; examples include the base excision repair enzymes endonuclease VIII-like 1 and 7,8-dihydro-8-oxoguanine DNA glycosylase. In addition, expression of the enzyme DNA polymerase β decreases in brain cells during normal aging, and experimental reduction of DNA polymerase β expression triggers neuronal death and cognitive deficits in a mouse model of AD with Aβ and p-Tau pathology. It was recently reported that neuronal DNA repair can be enhanced by activation of glutamate receptors and BDNF, suggesting that age-related decrements in synaptic plasticity and neurotrophic support may contribute to increased neuronal DNA damage in ILOD.
Studies of human subjects have shown that regular physical exercise, particularly aerobic running, improves brain health as indicated by improved mood and enhanced cognitive function. In elderly subjects, exercise interventions can enhance cognitive performance and may preserve or increase gray and white matter volumes in some brain regions. Importantly, with regard to the main topic of the present article is evidence from human epidemiological data and studies of animal models suggesting that regular exercise can forestall ILOD and protein aggregation-related pathologies including Aβ, p-Tau and α-synuclein. Similarly, DER has been reported to ameliorate cognitive deficits and lessen accumulation and/or neurotoxicity of Aβ in animal models of AD. Environmental enrichment can also lessen Aβ and Tau pathologies and improve cognitive function in transgenic mouse models of ILOD. With regard to human studies there is evidence that individuals who avoid weight gain and central adiposity in midlife, and those who regularly engage in intellectually challenging endeavors, are at reduced risk for ILOD. The question then becomes ‘what are the molecular and cellular mechanisms by which DER, exercise and cognitively stimulating environments can counteract age-related cellular stress and disease processes involved in ILOD?’

DER can robustly increase both the average and maximum lifespan in a range of mammalian species and can protect neurons against dysfunction and degeneration in animal models of AD, PD, Huntington’s disease, stroke and epileptic seizures. DER can also counteract the major age- and disease-related adverse conditions that may trigger and exacerbate ILOD, including oxidative stress, bioenergetics deficits, excitotoxicity, inflammation and proteotoxic pathologies. Compared to DER, voluntary running wheel exercise has more modest effects on lifespan, and markers of brain oxidative stress and inflammation. Similar to exercise, environmental enrichment has been reported to reduce brain oxidative stress and inflammation in animal models of ILOD.

Neurotrophic factors produced in an activity-dependent and cellular energy status-responsive manner mediate adaptive neuroplastic responses to exercise, fasting and cognitive enrichment. The cellular responses to these challenges include long-term potentiation of synaptic transmission, dendritic spine formation and hippocampal neurogenesis. Exercise and cognitive challenges induce BDNF expression in the hippocampus and other brain regions. The evidence that BDNF plays critical roles in multiple beneficial effects of exercise and enriched environments on hippocampal plasticity in mice and rats is extensive. Whether BDNF is critical for protection against ILOD by exercise, DER and intellectual challenges remains to be established. However, a recent study provided evidence that a socially enriched environment can rescue memory deficits in a mouse model of AD by a BDNF-dependent mechanism. Some studies have reported that exercise can increase BDNF levels in a behaviorally relevant manner.

**Figure 3.** Intermittent bioenergetic challenges forestall ILOD by stimulating adaptive stress response pathways. (a) As with other species, humans evolved in environments where there was competition for food, mates and other resources. Accordingly, selection favored individuals whose brains functioned best when they were hungry, physically active and under stress. In response to the challenges (exercise, dietary energy restriction/fasting, intellectual challenges and consumption of noxious phytochemicals) neurons experience mild bioenergetic and oxidative stress. The neurons respond adaptively by activating signaling pathways that improve their ability to cope with more severe stress and resist disease. These neuroprotective pathways are triggered by calcium, reactive oxygen species (ROS) and increased energy demand, and involve kinases such as AMP-activated kinase (AMPK), and transcription factors such as cyclic AMP response element binding protein (CREB). The latter pathways increase autophagy, and induce the expression of genes encoding neurotrophic factors, antioxidant enzymes and DNA repair enzymes. During the challenges there is a reduction of mTOR (mammalian target of rapamycin) activity and protein synthesis. Once the challenge is over (e.g., food has been acquired) there is a recovery period that involves eating, relaxing and sleeping. During the recovery period mTOR activity, protein synthesis and mitochondrial biogenesis increase, and the growth of axons and dendrites, formation of new synapses and neurogenesis (the production of new neurons from stem cells) occur. Because of the adaptive stress responses induced during the challenge period levels of oxidative stress, DNA damage and protein aggregation are reduced. This model predicts that individuals who regularly engage in cycles of challenges and recovery periods during their adult life will exhibit optimal brain function and will be relatively resistant to the development of ILOD. (b) An example of a lifestyle that includes intermittent challenges as a means of optimizing brain health. In this case the person fasts (water or non-caloric beverages only) on the first day, while engaging in intellectual challenges (light bulb) and physical exercise (running). On the next day the subject eats several meals, runs, relaxes and engages in critical thinking.
the serum or plasma of human subjects, although the source of the circulating BDNF is unknown, and it is unclear whether there is a direct relationship between brain and blood BDNF levels. In addition to BDNF, insulin-like growth factor 1 mediates adaptive responses of the brain to exercise. Circulating insulin-like growth factor 1 can enter the brain and affect gene expression in ways that stimulate neurogenesis and angiogenesis, and enhance synaptic plasticity and cognitive function.

Much as occurs in skeletal muscle cells in response to vigorous exercise, recent findings suggest that bioenergetic challenges increase the ability of neurons to generate ATP by stimulating mitochondrial biogenesis (the growth and division of mitochondria). During exercise, Ca2+ influx and reactive oxygen species activate adenosine monophosphate-activated kinase (AMPK) and the transcription factor peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) in muscle cells. PGC-1α then induces the expression of multiple genes encoding proteins required for mitochondrial biogenesis. In one study, treadmill training resulted in increased levels of PGC-1α and mitochondrial DNA electron transport chain proteins in multiple brain regions of mice, suggesting an increase in mitochondrial biogenesis.

Combining intermittent exercise with DER enhances BDNF production and increases dendritic spine density in normal and diabetic mice, although it is unclear if DER enhances the effects of exercise on neuronal mitochondrial biogenesis. However, recent findings suggest that BDNF may mediate mitochondrial biogenesis in response to exercise, DER and cognitive challenges. As evidence, BDNF induces PGC-1α expression and mitochondrial biogenesis in hippocampal neurons. Moreover, the ability of BDNF to promote synapse formation requires PGC-1α expression, suggesting the possibility that mitochondrial biogenesis plays a role in the stimulation of synapse formation by exercise and DER, and the protection of synapses against degeneration in ILOD.

While it is evident that regular engagement in cognitive challenges can promote maintenance of cognitive abilities during aging, an understanding of why intermittent exercise and DER also enhance cognitive abilities and may forestall ILOD is clarified by evolutionary considerations. Our human ancestors, and the species that preceded them, were regularly challenged with the necessity of acquiring sufficient food resources for survival and to support reproduction. Presumably, individuals whose cognitive abilities were best when they were hungry, physically fit, and actively exploring and encoding mental maps of their environment would have a survival advantage. Nervous systems that responded adaptively to the challenge of competing for limited amounts of food were those that were selected for. Arguably, many of the higher cognitive abilities that humans now possess evolved for the purpose of securing food. Indeed, it has been proposed that the great expansion of the visual and prefrontal cortices during hominid evolution was driven by the need to develop highly efficient foraging strategies. At a fundamental level, the essence of the superior capabilities of the human brain, including invention, imagination, efficient decision-making, creativity and language, is based on pattern processing. A prediction of the superior pattern-processing hypothesis of human brain evolution is that physical exertion, DER and complex cognitive challenges enhance pattern-processing capability. Direct support for the latter prediction comes from recent studies showing that wheel running enhances spatial pattern separation in mice and that exercise improves cognitive function across a range of domains in human subjects. ILOD involves progressive deficits in pattern processing resulting from the degeneration of neurons that mediate pattern processing. It is therefore reasonable to conclude that the same challenges that shaped the evolution of the human brain over millions of years can also sustain brain structure and function during aging.

FUTURE DIRECTIONS AND IMPLICATIONS FOR THE PREVENTION AND TREATMENT OF ILOD

While drug companies, neurologists and many researchers who study neurodegenerative disorders emphasize the need to develop and prescribe drugs specific for prototypical ILODs (i.e., AD, FTD, LBD, HSA), the findings reviewed above suggest that the mosaic nature of the molecular and cellular neuropathological landscape of ILODs is more amenable to interventions that stimulate multiple pathways that bolster neuronal plasticity and stress resistance. The advantages of prescriptions for intermittent challenges (exercise, DER and intellectual endeavors) are manifest and include (1) the fact that our brains (and bodies) evolved so as to benefit from the challenges; (2) the relative lack of any adverse side effects; and (3) little or no cost to the patient. The barriers to intermittent challenge-based interventions revolve mostly around the economic and political forces that prevent their implementation, namely the pharmaceutical, processed food and health-care industries. Put simply, the profits of the latter industries would suffer greatly if prescriptions for intermittent challenge-based lifestyles were widely implemented such that far fewer individuals developed chronic diseases including ILOD. Therefore, a major future direction for research on intermittent challenges that engage adaptive stress response pathways is to better understand the specific machinations of the pharmaceutical and food industries that have fostered the rising tide of populations that are encouraged to overeat, and then to take drugs to treat the symptoms of the many ailments they develop.

During the challenge period, neuronal activity and energy demand increase, and kinases (e.g., CaMKII and AMPK) and transcription factors (e.g., CREB and PGC-1α) are activated. As a consequence, the expression of genes encoding proteins involving autophagy, free radical metabolism and DNA repair is increased. This challenge places the cells in a ‘preservation mode’ in which mammalian target of rapamycin activity and overall protein synthesis are reduced, while pathways that bolster stress resistance are engaged. During the recovery period, protein synthesis increases, mitochondrial biogenesis occurs, and neurite outgrowth, synapse formation and neurogenesis occur. In the absence of challenges (i.e., a ‘couch potato’ lifestyle), the pathways normally activated by the challenges are downregulated, resulting in the accumulation of ‘molecular toxic waste’ including aggregated Aβ, p-Tau, TDP-43 and α-synuclein, and dysfunctional mitochondria. Future research on the effects of challenge–recovery cycles should include (1) expanding and refining an understanding of the molecular and cellular responses of brain cells to different patterns and intensities of challenges, and the impact of individual and combined challenges on functional outcomes in animal models relevant to ILODs; (2) randomized controlled trials to establish the effects of intermittent challenges on brain function and chemistry in healthy subjects, individuals at risk for ILOD, and individuals in the early symptomatic stage of ILOD; and (3) development and implementation of specific prescriptions for intermittent challenge routines to promote and sustain brain health during aging (e.g., Figure 3b).

Hormesis occurs when transient exposure of a cell or organism to a low to moderate level of an agent or condition (e.g., ingestion of a chemical, high temperature, exercise, food deprivation) induces an adaptive/beneficial response, while exposure to higher and/or sustained levels of the agent or condition results in detrimental effects on the cell or organism. Thus, a biphasic dose–response curve is a defining feature of hormesis. In addition...
to the evidence suggesting that exercise, DER and intellectual challenges may forestall ILOD by hormesis-based mechanisms; it has been shown that chemical challenges can activate adaptive stress response pathways and protect neurons in models relevant to ILOD. Indeed, emerging findings suggest that some chemicals in fruits and vegetables are 'toxins' from the perspective of plant evolution—they are noxious phytochemicals that function as natural pesticides/antifeedants. Examples of such neuroprotective 'hormetic phytochemicals' include sulforaphane, curcumin, epicatechins and resveratrol. Considerable further basic and translational research will be required to determine if and to what extent such phytochemicals, or man-made drugs that activate hormetic pathways, can counteract the pathological cascades believed to occur in ILOD. Nevertheless, a broader appreciation of the potential for approaches that engage intrinsic pathways that bolster neuroplasticity and stress resistance may help accelerate the development of viable prophylactic and treatment approaches to halt and reverse the emerging ILOD crisis.

ACKNOWLEDGEMENTS

This work was supported by the Intramural Research Program of the National Institute on Aging. The author declares that no funding was received.

COMPETING INTERESTS

The author declares no conflict of interest.

REFERENCES

1 Dowling NM, Tomaszewski Farias S, Reed BR, Sonnen JA, Strauss ME, Schneider JA et al. Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. J Int Neuropsychol Soc 2017; 12: 602–614.

2 Cheolerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP et al. Neuro-pathologic correlates of cognition in a population-based sample. J Alzheimer Dis 2013; 36: 699–709.

3 Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013; 70: 1418–1424.

4 Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68: 270–281.

5 Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease. Brain 2014; 137: 1533–1549.

6 Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al. Alzheimers Dement 2012; 8: 1–13.

7 Geddes JW, Tekiwal TN, Soutainan NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer’s disease. Neurobiol Aging 1997; 18: 599–5105.

8 Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 2008; 31: 454–463.

9 Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau. J Neuropathol Exp Neurol 2012; 71: 36–52.

10 Aoki N, Murray ME, Ogaki K, Fuijoka S, Rutherford NJ, Rademakers R et al. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP type A. Acta Neuropathol 2015; 129: 53–64.

11 Rosenberg CK, Pericak-Vance MA, Saunders AM, Gilbert JR, Gaskell PC, Hulette CM. Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APPP17 gene mutation. Acta Neuropathol 2000; 100: 145–152.

12 Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 2005; 62: 1821–1830.

13 Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004; 430: 631–639.

14 Mattson MP. Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab 2012; 16: 706–722.

15 Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH et al. ABCG9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014; 127: 825–843.

16 Nelson PT, Wang WX, Parich AB, Monsell SE, Valladares O, Ellingson SR et al. Reassessment of risk genotypes (GRN, TMEM106B, and ABC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 2014; 73: 75–84.

17 Hanson JC, Lippa CF. Lewy body dementia. Int Rev Neurobiol 2009; 84: 215–228.

18 Ferencz B, Gerritsen L. Genetics and underlying pathology of dementia. Neuropsychol Rev 2015; 25: 113–124.

19 Jellinger KA. Neurobiology of cognitive impairment in Parkinson’s disease. Expert Rev Neurother 2012; 12: 1451–1466.

20 Houlden H, Singleton AB. The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol 2012; 124: 325–338.

21 Venderova K, Park DS. Programmed cell death in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: pi009395.

22 Kovacs GG, Millenkovic I, Wohrer A, Höftberger R, Gelpi E, Haberler C et al. Non-Alzheimer neurodegenerative pathways and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365–384.

23 Josephs KA, Whitgel JD, Weigand SD, Murray ME, Tosakulwong N et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol 2014; 127: 811–824.

24 Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA et al. Neurobiology of cognitive impairment in Parkinson’s disease. Acta Neuropathol 2014; 127: 811–824.

25 Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gómez-Isla T, Betensky RA et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014; 75: 597–601.
53 Keller JN, Pang Z, Geddes JW, Begley JG, Gernerry A, Waeg G et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69: 273–284.

54 Kostjina AM, Kuttunnen MI, Goldsteins G, Keinanen R, Salminen A, Ort M et al. Beta-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci USA 2002; 99: 1610–1615.

55 Huang X, Moir RD, Tanzé R, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann N Y Acad Sci 2004; 1012: 153–163.

56 Fang F, Lue FY, Yan S, Xu H, Luddy JS, Chen D et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 2010; 24: 1043–1055.

57 Harris H, Rubinstein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurosci 2011; 8: 108–117.

58 Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983–997.

59 Quiroz-Baez R, Flores-Domínguez D, Arias C. Synaptic aging is associated with mitochondrial dysfunction, reduced antioxidant contents and increased vulnerability to amyloid-β toxicity. Curr Alzheimer Res 2013; 10: 324–331.

60 Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuroeen 1991; 7: 695–699.

61 Talbot K, Wang HY, Kazi H, Han LY, Bakhsi RP, Stucky A et al. Reduced BDNF expression in human brain and cerebellum of 3xTgAD mice. J Alzheimers Dis 2008; 31: 316–326.

62 Atencio S, Silhol M, Moulleir F, Meffre J, Höllinger I, Maurice T et al. The effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo. J Neurochem 2014; 129: 141–152.

63 Yao Z, Wood NW. Cell death pathways in Parkinson’s disease. Mol Cell 2010; 40: 333–344.

64 McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron 2013; 79: 16–29.

65 Miller DB, O’Callaghan JP. Aging, stress and the hippocampus. Ageing Res Rev 2005; 4: 123–140.

66 Texel SJ, Mattsson MP. Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer’s disease. Antioxid Redox Signal 2011; 14: 1519–1534.

67 Rothman SM, Mattsson MP. Activity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespan. Neuroscience 2013; 239: 228–240.

68 Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 2009; 4: e5420.

69 Calabrese F, Guidotti G, Racagni G, Riva MA. Reduced neuroplasticity in aged rats: a role for the neurotrophin brain-derived neurotrophic factor Neurobiol Aging 2013; 34: 2766–2776.

70 Sen A, Nelson TJ, Alkon DL. ApoE4 and Aβ oligomers reduce BDNF expression via HDAC nuclear translocation. J Neurosci 2015; 35: 7538–7551.

71 Nagahara AH, Merrill DA, Copolla G, Tsukada S, Schroeder BE, Shaked GM et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 2009; 15: 331–337.

72 Cheng A, Wan R, Yang J, Kamimura N, Son TG, Ouyang X et al. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun 2012; 3: 1250.

73 Arumugam TV, Phillips TM, Cheng A, Morell CH, Mattsson MP, Wan R. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurosci 2010; 17: 41–52.

74 Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germerry A et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 2018; 18: 687–697.

75 Esposito L, Raber J, Kekkonis L, Yan F, Yu QG, Bién-Ly N et al. Reduction in mitochondrial superoxide dismutase modulates Alzheimer’s disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci 2006; 26: 5167–5179.

76 Moblov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinnerfeld D et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2007; 2: e536.

77 Mattsson MP, Meffert MK. Roles for Nf-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006; 13: 852–860.

78 Mazzuferi M, Kumar G, van Eyll J, Danis B, Foceri P, Kaminski RM. Nrf2 defense pathway: experimental evidence for its protective role in epilepsy. Ann Neurol 2013; 74: 560–568.

79 Huy DH, Emerson SS, Jo DG, Mattsson MP, de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci USA 2006; 103: 19908–19912.

80 Huy DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND et al. The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423–429.

81 Navarro A, Boveris A. The mitochondrial energy transduction system and aging: a mitochondrial model. J Physiol 2006; 572: 37–43.

82 Mazzuferi M, Kumar G, van Eyll J, Danis B, Foerch P, Kaminski RM. Nrf2 defense pathway: experimental evidence for its protective role in epilepsy. Ann Neurol 2013; 74: 560–568.

83 Hyun DH, Emerson SS, Jo DG, Mattsson MP, de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci USA 2006; 103: 19908–19912.

84 Huy DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND et al. The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423–429.

85 Navarro A, Boveris A. The mitochondrial energy transduction system and aging. J Physiol 2006; 572: 37–43.

86 Mazzuferi M, Kumar G, van Eyll J, Danis B, Foceri P, Kaminski RM. Nrf2 defense pathway: experimental evidence for its protective role in epilepsy. Ann Neurol 2013; 74: 560–568.

87 Hyun DH, Emerson SS, Jo DG, Mattsson MP, de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci USA 2006; 103: 19908–19912.

88 Huy DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND et al. The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423–429.

89 Navarro A, Boveris A. The mitochondrial energy transduction system and aging. J Physiol 2006; 572: 37–43.

90 Huy DH, Emerson SS, Jo DG, Mattsson MP, de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci USA 2006; 103: 19908–19912.

91 Huy DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND et al. The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423–429.

92 Huy DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND et al. The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 2010; 225: 423–429.
103 Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J

105 Liu D, Croteau DL, Souza-Pinto N, Pitta M, Tian J, Wu C

108 Yang JL, Tadokoro T, Keijzers G, Mattson MP, Bohr VA. Neurons ef

109 Stranahan AM, Mattson MP. Recruiting adaptive cellular stress responses for

112 Brené S, Bjørnebekk A, Aberg E, Mathé AA, Olson L, Werme M. Running is

114 Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L

116 Dimatelis JJ, Hendricks S, Hsieh J, Vlok NM, Bugarith K, Daniels WM

118 García-Mesa Y, López-Ramos JC, Giménez-Llort L, Revilla S, Guerra R, Gruart A

119 Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 2007; 26: 212–220.
Herring A, Blome M, Ambrière O, Sachser N, Paulus W, Keyvan K. Regulation of cerebral oxidative stress following environmental enrichment in mice with Alzheimer-like pathology. Brain Pathol 2010; 20: 166–175.

Herring A, Lewejohann L, Panzer AL, Donath A, Kröl O, Sachser N et al. Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiol Dis 2011; 42: 530–538.

Kesslak JP, So V, Choi J, Cotman CW, Gomez-Pinilla F. Learning upregulates brain-derived neurotrophic factor messenger ribonucleic acid: a mechanism to facilitate encoding and circuit maintenance? Behav Neurosci 1998; 112: 1012–1019.

Oliff HS, Berchtold NC, Isackson P, Cotman CW. Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Brain Res Mol Brain Res 1998; 61: 147–153.

Llorens-Martín M, Torres-Alemán I, Trejo JL. Role of serum insulin-like growth factor-I in mammalian brain aging. Growth Horm IGF Res 2004; 14 Suppl A: 539–543.

Voss MW, Erickson KI, Prakash RS, Chaddock L, Kim JS, Alves H et al. Neurobiological markers of exercise-related brain plasticity in older adults. Brain Behav Immun 2013; 28: 90–99.

Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 2005; 4: 195–212.

Trejo JL, Carro E, Lopez-Lopez C, Torres-Aleman I. Role of serum insulin-like growth factor I in mammalian brain aging. Growth Horm IGF Res 2004; 14 Suppl A: 539–543.

Yan H, Mitschelen M, Bixler GV, Brucklacher RM, Farley JA, Han S et al. Circulating IGF1 regulates hippocampal IGF1 levels and brain gene expression during adolescence. J Endocrinol 2011; 211: 27–37.

Holloszy JO. Regulation of mitochondrial biogenesis and GLUT4 expression by exercise. Compr Physiol 2011; 1: 921–940.

Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol (1985) 2011; 111: 1066–1071.

Passingham RE, Wise SP. The Neurobiology of the Prefrontal Cortex: Anatomy, Evolution and the Origin of Insight. Oxford University Press: Oxford, UK, 2012.

Silver MA, Kastner S. Topographic maps in human frontal and parietal cortex. Trends Cogn Sci 2009; 13: 488–495.

Mattson MP. Superior pattern processing is the essence of the evolved human brain. Front Neurosci 2014; 8: 265.

Creer DJ, Romberg C, Sakaida LM, van Praag H, Bussey TJ. Running enhances spatial pattern separation in mice. Proc Natl Acad Sci USA 2010; 107: 2367–2372.